发布求助
文献互助 智能选刊 最新文献

Future Prescriber最新文献

筛选
英文 中文
IL-6 inhibition in the treatment of rheumatoid arthritis IL-6抑制在类风湿关节炎治疗中的作用
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.35
Peter Taylor MA, PhD, FRCP
{"title":"IL-6 inhibition in the treatment of rheumatoid arthritis","authors":"Peter Taylor MA, PhD, FRCP","doi":"10.1002/fps.35","DOIUrl":"10.1002/fps.35","url":null,"abstract":"<p>The armentarium of potential therapeutics for rheumatoid arthritis (RA) has grown with the identification of relevant disease molecules. Of these, biologic therapeutics targeting tumour necrosis factor-alpha (TNF-alpha), particularly when used in combination with oral methotrexate, have enjoyed notable success in suppressing inflammation and markedly inhibiting the progression of structural damage previously thought to be an unavoidable characteristic of RA.<sup>1,2</sup> However, despite the unprecedented clinical and commercial successes of TNF inhibitors, their availability is restricted by high costs and the failure of a substantial proportion of patients to demonstrate significant clinical responses. Copyright © 2007 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"8 3","pages":"16-21"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.35","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86145420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
HIV management: emerging therapies in an evolving field 艾滋病毒管理:一个不断发展的领域的新疗法
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.30
Mark Gompels MD, Alison Chisholm MSc
{"title":"HIV management: emerging therapies in an evolving field","authors":"Mark Gompels MD,&nbsp;Alison Chisholm MSc","doi":"10.1002/fps.30","DOIUrl":"10.1002/fps.30","url":null,"abstract":"<p>Efforts to combat the Human Immunodeficiency Virus (HIV) began in earnest in the late 1980s following the identification and isolation of HIV as the pathogen of the Acquired Immunodeficiency Syndrome (AIDS). Multiple-drug therapy, known as highly active antiretroviral therapy (HAART), became available in the 1990s and has become the backbone of HIV medication treatment. Understanding of how to optimise its use and effectiveness continues to grow, and is reflected by the emergence of novel agents and new classes of drugs. Copyright © 2007 Wiley Interface Ltd</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"8 2","pages":"9-16"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.30","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84832234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving CVD risk assessment with eGFR 用eGFR改善心血管疾病风险评估
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.22
Sue Lyon
{"title":"Improving CVD risk assessment with eGFR","authors":"Sue Lyon","doi":"10.1002/fps.22","DOIUrl":"10.1002/fps.22","url":null,"abstract":"<p>A quiet revolution is taking place within the NHS as laboratories grad-ually switch from serum creatinine to estimated glomerular filtration rate (eGFR) as the prime measure of renal function. This change follows recommendations in the National Service Framework for Renal Services,1 but the move will have an impact far beyond the renal com-munity, affecting health profess-ionals and patients throughout primary and secondary care. Copyright © 2006 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 1","pages":"26-28"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.22","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88537000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in the management of inflammatory bowel disease 炎症性肠病的治疗进展
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.31
James Jupp BM MRCP, Sally Parry MD, MRCP
{"title":"Advances in the management of inflammatory bowel disease","authors":"James Jupp BM MRCP,&nbsp;Sally Parry MD, MRCP","doi":"10.1002/fps.31","DOIUrl":"10.1002/fps.31","url":null,"abstract":"<p>Inflammatory bowel disease is a common and complicated disorder that has a great impact on the lives of those affected. This review discusses the properties and uses of the treatments available and possible future advances in therapy. Copyright © 2007 Wiley Interface Ltd</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"8 2","pages":"17-23"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.31","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74654648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trastuzumab: preparation and planning will avoid chaos 曲妥珠单抗:准备和计划将避免混乱
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.19
Steve Chaplin MRPharmS
{"title":"Trastuzumab: preparation and planning will avoid chaos","authors":"Steve Chaplin MRPharmS","doi":"10.1002/fps.19","DOIUrl":"10.1002/fps.19","url":null,"abstract":"<p>Trastuzumab has been shown to improve disease-free, and overall, survival in women with early HER2-positive breast cancer. It is undergoing rapid appraisal by NICE with the aim of providing prompt guidance for use within the NHS. The DOH has pledged to support its use, yet without increasing PCT funding for support services and additional drug costs. The criteria by which PCTs can decide or decline to pay for treatment remain unclear. Copyright © 2006 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 1","pages":"7-12"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.19","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84167110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pegaptanib sodium for age-related macular degeneration 培加他尼钠治疗老年性黄斑变性
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.27
Sobha Sivaprasad FRCS, Phil Hykin FRCOphth
{"title":"Pegaptanib sodium for age-related macular degeneration","authors":"Sobha Sivaprasad FRCS, Phil Hykin FRCOphth","doi":"10.1002/fps.27","DOIUrl":"10.1002/fps.27","url":null,"abstract":"","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 3","pages":"20-24"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.27","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72628826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Novel metabolic drugs for the management of type 2 diabetes 治疗2型糖尿病的新型代谢药物
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.25
Professor Anthony Barnett BSc (Hons), MD, FRCP, Dr Srikanth Bellary MRCP
{"title":"Novel metabolic drugs for the management of type 2 diabetes","authors":"Professor Anthony Barnett BSc (Hons), MD, FRCP,&nbsp;Dr Srikanth Bellary MRCP","doi":"10.1002/fps.25","DOIUrl":"10.1002/fps.25","url":null,"abstract":"","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 3","pages":"7-14"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.25","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79194693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Aromatase inhibitors in preventing breast cancer recurrence 芳香酶抑制剂预防乳腺癌复发
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.21
Robert Carpenter
{"title":"Aromatase inhibitors in preventing breast cancer recurrence","authors":"Robert Carpenter","doi":"10.1002/fps.21","DOIUrl":"10.1002/fps.21","url":null,"abstract":"","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 1","pages":"21-24"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.21","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81958643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liraglutide: a new option in the management of type 2 diabetes 利拉鲁肽:治疗2型糖尿病的新选择
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.10
Milan K Piya, Abd A Tahrani, Anthony H Barnett
{"title":"Liraglutide: a new option in the management of type 2 diabetes","authors":"Milan K Piya,&nbsp;Abd A Tahrani,&nbsp;Anthony H Barnett","doi":"10.1002/fps.10","DOIUrl":"10.1002/fps.10","url":null,"abstract":"<p>Type 2 diabetes mellitus (T2DM) is a global epidemic with an expected prevalence of 380 million in 2025 worldwide<sup>1</sup> and over 2.5 million by 2010 in the UK.<sup>2</sup> Diabetes is a progres-sive disease which leads to macro and microvascular complications and reduced life expectancy.<sup>2</sup> Furthermore, diabetes-related complications have been shown to worsen patients' quality of life.<sup>3,4</sup> Copyright © 2008 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 2","pages":"6-12"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.10","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74787606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Treatment options in pulmonary arterial hypertension 肺动脉高压的治疗选择
Future Prescriber Pub Date : 2008-08-08 DOI: 10.1002/fps.29
Mark Toshner MD
{"title":"Treatment options in pulmonary arterial hypertension","authors":"Mark Toshner MD","doi":"10.1002/fps.29","DOIUrl":"10.1002/fps.29","url":null,"abstract":"<p>Pulmonary arterial hypertension (PAH) is a rare, severe and progressive disease characterised by raised pressures in the arteries in the lungs leading to right heart failure and, historically, a median life expectancy of 2.8 years with-out targeted treatment.<sup>1</sup> Pathologically, it is characterised by a thickening of the muscular layer of the arteries, dysfunction of the vessel walls, and abnormal growth of supporting cells such as fibroblasts. Copyright © 2007 Wiley Interface Ltd</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"8 2","pages":"5-8"},"PeriodicalIF":0.0,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.29","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75770608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信